Nalaganje...
Clinical Experience with α-Particle–Emitting (211)At: Treatment of Recurrent Brain Tumor Patients with (211)At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
α-Particle–emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-parti...
Shranjeno v:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2007
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2832604/ https://ncbi.nlm.nih.gov/pubmed/18077533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.046938 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|